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Abstract 
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. High adenoma 
miss rates, especially seen in high-risk patients, demand for better endoscopic detection. By 
fluorescently ‘highlighting’ specific molecular characteristics, endoscopic molecular imaging has great 
potential to fulfill this need. To implement this technique effectively, target proteins that distinguish 
adenomas from normal tissue must be identified. In this study we applied in silico Functional Genomic 
mRNA (FGmRNA) profiling, which is a recently developed method that results in an enhanced view on 
the downstream effects of genomic alterations occurring in adenomas on gene expression levels. 
FGmRNA profiles of sporadic adenomas were compared to normal colon tissue to identify 
overexpressed genes. We validated the protein expression of the top identified genes, AXIN2, CEMIP, 
CD44 and JUN, in sporadic adenoma patient samples via immunohistochemistry (IHC). CD44 was 
identified as the most attractive target protein for imaging purposes and we proved its relevance in 
high-risk patients by demonstrating CD44 protein overexpression in Lynch lesions. Subsequently, we 
show that the epithelial splice variant CD44V6 is highly overexpressed in our patient samples and we 
demonstrated the feasibility of visualizing adenomas in ApcMin/+ mice in vivo by using a fluorescently 
labeled CD44v6 targeting peptide. In conclusion, via in silico functional genomics and ex vivo protein 
validation, this study identified CD44 as an attractive molecular target for both sporadic and high-risk 
Lynch adenomas, and demonstrates the in vivo applicability of a small peptide drug directed against splice 
variant CD44v6 for adenoma imaging. 
Key words: Functional Genomics; Cancer Genetics; Colorectal adenomas; Molecular Targeted Imaging; CD44 / 
CD44v6. 
Introduction 
Despite its decreasing mortality, colorectal 
cancer (CRC) is still the third most common cause of 
cancer-related death worldwide (1). The development 
of CRC is a multistep process, known as the 
adenoma-carcinoma sequence: In approximately 10-20 
years, normal colonic mucosa can slowly transform 
via premalignant adenomatous polyps into invasive 
cancer (2). The adenoma-carcinoma sequence is 
characterized by consecutive genetic alterations, such 
as common ‘driver’ mutations in the APC gene, the 
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proto-oncogene K-RAS, the tumor suppressor gene 
TP53 and activation of the Wnt-signaling pathway (3). 
Early endoscopic identification of adenomas and 
subsequent radical removal is the keystone in 
breaking the adenoma-carcinoma sequence, thereby 
preventing CRC development. Nevertheless, early 
detection and radical removal are still challenging 
tasks due to non-specific tissue morphology. When 
using standard white-light endoscopy, this results in 
detection miss rates of up to 25% for sporadic 
adenomas (4). In particular flat and small lesions, 
often seen in high-risk populations like Lynch 
patients, are notoriously difficult to detect, resulting 
in adenoma detection miss rates of up to 50% (5). 
Especially in these patients, missed lesions can 
rapidly progress to cancer, underscoring the necessity 
of improving endoscopic detection strategies. 
Therefore, endoscopic techniques based on molecular 
imaging are emerging (6). Molecular imaging can 
improve optical discrimination of aberrant tissue by 
labeling specific molecular characteristics with 
targeted fluorescent monoclonal antibodies or peptide 
probes. Molecular imaging preferably targets proteins 
that are selectively overexpressed in dysplastic or 
malignant cells. Protein overexpression can be the 
downstream effect of genomic alterations that occur 
frequently within the adenoma-carcinoma sequence. 
Thus, by fluorescently ‘highlighting’ the 
overexpressed target proteins within dysplastic 
lesions, an optical molecular method is created that 
can serve as a ‘red-flag’ strategy for distinguishing 
dysplastic tissue in real-time during endoscopic 
evaluation.  
Effective implementation of this molecular- 
based technique in gastrointestinal endoscopy 
requires identification of target proteins that can 
detect dysplasia with a high specificity. To identify 
relevant target proteins, DNA changes that occur in 
adenomas can be addressed; the difference between 
adenomas and normal colorectal tissue is that 
adenomas exhibit genomic alterations that might lead 
to downstream changes in gene expression levels. 
These changed gene expression levels, in turn, 
influence the downstream cellular phenotype, and by 
doing so, they affect protein expression levels. 
Nevertheless, these genomically driven changes in 
gene expression levels are rather subtle and usually 
overshadowed by non-genetic processes, such as the 
circadian rhythm or prosprandial metabolic 
influences (7). To be able to identify target proteins 
that distinguish adenomas from normal colorectal 
tissue, we therefore applied a recently introduced 
method called functional genomic mRNA (FGmRNA) 
profiling. With FGmRNA-profiling we are able to 
correct gene expression data for major non-genetic 
factors, thereby enhancing our view on the 
downstream effect of genomic alteration occurring in 
adenomas on gene expression levels (7). 
Subsequently, to evaluate the protein expressions 
levels and validate our FGmRNA-profiling results, we 
performed immunohistochemistry (IHC) analyses for 
the top five genes that were identified. In addition, we 
evaluated CD44 expression in Lynch patient material. 
Finally, we performed ApcMin/+ mice experiments 
evaluating the applicability of a small peptide drug 
directed against the CD44 splice variant v6 for 
targeted adenoma imaging purposes. 
Material and methods 
In silico functional genomics: Functional 
Genomic mRNA (FGmRNA) Profiling  
We used FGmRNA-profiling to capture the 
downstream effect of genomic alterations at gene 
expression levels. For a detailed description of this 
bioinformatics method we refer to Fehrmann et al.(7) 
In short, by performing a principal component 
analysis (PCA) on expression profiles of publicly 
available samples, Fehrmann et al. demonstrated that 
a limited number of ‘Transcriptional Components’ 
(TCs) capture the major regulators of the mRNA 
transcriptome. Subsequently, a subset of TCs that 
described non-genetic regulatory factors was 
identified. These non-genetic TCs were used as 
covariates to correct microarray expression data, with 
which they observed that the residual expression 
signal (i.e. FGM profile) captures the downstream 
consequences of genomic alterations on gene 
expression levels.  
In the present study, we generated FGmRNA 
profiles for adenomas and healthy control colorectal 
mucosa samples. We used microarray expression 
profiles from the Gene Expression Omnibus (GEO - 
www.ncbi.nlm.nih.gov/geo/), previously described 
by Heijink et al.(8) In short, we included data from 
existing Affymetrix intensity files (CEL files) of 
mRNA from adenomas and healthy control colorectal 
mucosa hybridized to HG-U133 plus 2.0 (Affymetrix, 
Santa Clara, CA, USA). Pre-processing and 
aggregation of CEL files was performed with 
Affymetrix Power Tools version 1.15.2, using 
apt-probe set-summarize and applying the robust 
multi-array average (RMA) algorithm, using the 
Affymetrix GeneChip Array CDF layout files 
(downloaded March 2014). We used the probe 
annotation file provided by Affymetrix (version 34). 
Quality control was performed using Principal 
Component Analysis (PCA) on the sample correlation 
matrix as described previously.(8) 
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Table 1: Immunohistochemistry (IHC) details and methods. 
Target protein Protein location Antigen retrieval 1st antibody 2nd /3rd antibody 
Axin-2 Cytoplasm Citrate buffer  
(10 mM, pH 6.0) 
Abcam, ab32197 [0.9 mg/ml] (1) 
Rabbit-anti-human, polyclonal,  
Incubation: 1.8 ug/ml, 60min/RT 
- GAR-HRP 1:100,  
- RAG-HRP 1:100, 30min/RT 
CEMIP Cytoplasm 
(ER membrane) 
Citrate buffer  
(10 mM, pH 6.0) 
Proteintech 
21129-1-AP [0.2 mg/ml] 
Rabbit-anti-human, polyclonal,  
 Incubation: 2 μg/ml, 60min/RT  
- GAR-HRP 1:100,  
- RAG-HRP 1:100, 30min/RT 
CD44 Cell membrane  Citrate buffer 
(10 mM, pH 6.0) 
Biolegend, IM7 [0.5 mg/ml] (2) 
Rat-anti-human, monoclonal 
Incubation: 5 μg/ml, overnight/4 °C 
- RARa-HRP 1:50,  
- GAR-HRP 1:100, 30min/RT 
CD44v6 
 
Cell membrane Citrate buffer  
(10 mM, pH 6.0) 
 
Abcam ab30436 [1 mg/ml] (3) 
Mouse-anti-human, monoclonal Incubation: 10 μg/ml, 
60min/RT  
-RAM-HRP 1:50,  
-GAR-HRP 1:50, 30min/RT 
 
Citrate buffer  
(10 mM, pH 6.0) 
Thermofisther 9A4 [0.5mg/ml] 
Rat-anti-mouse, monoclonal 
Incubation: 2.5 μg/ml, 60min/RT 
- RAR-HRP 1:100 
- GAR-HRP 1:100 
30 min/RT 
C-Jun Nucleus Citrate buffer  
(10 mM, pH 6.0) 
Santa Cruz (4) 
H-79, sc-1694 [0.2 mg/ml]  
Rabbit-anti-human, polyclonal  
Incubation: 0.8 μg/ml, 60min/RT 
- GAR-HRP 1:100,  
- RAG-HRP,1:100, 30min/RT 
 
CELF2 Nucleus 
Cytoplasm 
Varying buffers 
(pH6.0 – 9.0) 
 
Abcam, ab50734 [1mg/ml] 
Rabbit-anti-human, polyclonal  
Incubation: 1 - 20 μg/ml 
Varying incubation times 
(up to 12 hours) 
- GAR-HRP 1:100,  
- RAG-HRP,1:100, 30min/RT 
Abbreviations: RT: Room temperature; HRP: horseradish peroxidase; RARa: Rabbit-anti-Rat; GAR: goat-anti-rabbit; RAM: rabbit-anti-mouse; RAG, rabbit-anti-goat. References: (1) 
Winkler T et al. Wnt signaling activates Shh signaling in early postnatal intervertebral discs, and re-activates Shh signaling in old discs in the mouse. PLoS One 9:e9844 (2) NY Frank et al. 
ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma. Cancer Res. 2005 May 15;65(10):4320-33. (3) T Okada et al. Coexpression of EpCAM, CD44 
variant isoforms and claudin-7 in anaplastic thyroid carcinoma. PLoS One. 2014 Apr 11;9(4):e94487 (4) N Marqués et al. Regulation of protein translation and c-Jun expression by prostate 
tumor overexpressed 1. Oncogene. 2014 Feb 27;33(9):1124-34. 
 
Immunohistochemistry (IHC)  
IHC for FGmRNA validation-purposes was 
performed on formalin-fixed and paraffin-embedded 
(FFPE) tissue blocks containing sporadic high-grade 
dysplastic (HGD) adenomatous polyps (n=27) and 
normal adjacent colorectal mucosa (n=17). All tissue 
samples were derived from individuals who 
underwent colonoscopy between 2008 and 2013 at the 
University Medical Centre Groningen (UMCG, 
Groningen, the Netherlands). Furthermore, to 
evaluate CD44 expression in a high-risk CRC 
population, we performed a panCD44 staining on 
Lynch material. We collected FFPE tissue blocks 
derived from patients diagnosed with Lynch 
syndrome (LS) and who underwent surveillance 
colonoscopy or surgery between 1984 and 2011 at the 
UMCG. The LS tissue blocks contained LGD 
(low-grade dysplasia, n=63), HGD (n=58) or 
carcinoma tissue (n=32) with normal adjacent mucosa 
(n=52, n=42, n=21, respectively). In addition, next to 
the anti-panCD44 antibody, we also more selectively 
analyzed its epithelial splice variant CD44v6 in an 
extended sample-size of HGD sporadic adenomatous 
polyps (n=69) and normal adjacent mucosa (n=51).  
From each tissue block four-micron sections 
were cut, mounted on amino-propylethyoxy- 
silan-coated glass slides, deparaffinized in xylene and 
rehydrated in a series of alcohol dilutions. Secondly, 
heat-induced antigen retrieval was conducted using a 
10 mM citrate buffer (pH 6) followed by blocking of 
the endogenous peroxidase activity by incubation 
with a hydrogen-peroxide solution (3%), diluted with 
phosphate buffered saline (PBS). Subsequently, the 
primary antibodies against Axin-2, CEMIP, CELF2, 
CD44 (panCD44/CD44v6) and c-Jun were diluted in 
PBS and added as described in Table 1. Afterwards 
the second and third antibodies were diluted in PBS 
with 1% bovine serum albumin (BSA) and 1% human 
AB-serum and subsequently incubated, each for 30 
minutes. Finally, specific staining was visualized 
using 3,3’ diaminobenzidine (DAB) substrate 
chromogen solution and counterstaining of the nuclei 
with hematoxylin. 
All human tissue samples were handled 
according to the guidelines of the University Medical 
Centre Groningen (UMCG) ethics board 
(www.ccmo.nl) and the code of conduct for 
responsible use of human tissue (www.federa.org). 
IHC staining protocols were optimized for their 
applicability in colorectal tissue with help of a 
gastrointestinal pathologist (AK). To ascertain specific 
binding of the antibody, positive tissue controls 
(colorectal cancer) and negative controls using an 
aspecific IgG monoclonal antibody were included in 
each stained sample batch. Staining intensities of the 
epithelial cells were independently scored visually by 
two separate observers (EH, JM) using a 0-3 scale, as 
was the fraction of cells stained per intensity. 
Subsequently, H-scores were generated (continuous 
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scale: 0-300) by combining the evaluated intensity and 
frequency (formula used: 1x (percentage of cells weakly 
stained [1+] + 2x (percentage of cells moderately scored 
[2+]) + 3x (percentage of cells strongly stained [3+]), 
creating expression categories representative for 
overall protein expression for both adenoma and 
normal adjacent mucosa (0-100 = negative/low; 
101-200 = intermediate; 201-300 = high) (9). 
CD44v6-targeted fluorescence imaging of 
intestinal adenomas 
To evaluate the potential of CD44v6-targeted 
adenoma imaging, we performed an 
imaging-experiment using APCMin/+ mice. This animal 
model is highly representative for human colorectal 
adenoma research as the mutation of the APC gene is 
a known early event in the adenoma-carcinoma 
sequence (10). Furthermore, this model mimics the 
high-risk CRC population with familial adenomatous 
polyposis (FAP), where the underlying germ line APC 
mutation causes excessive polyp formation. In order 
to demonstrate the usefulness of this animal model in 
CD44v6-targeted imaging experiments, we performed 
anti-CD44v6 IHC on APCMin/+ mice intestines (n = 6; 
see Table 1 for IHC details). All animal experiments 
were approved by the local Animal Welfare 
Committee of the Karlsruhe Institute of Technology 
(KIT; license number 35-9185.81/G-247/15) and 
carried out in accordance with the German Animal 
Welfare Act of 2006. We used an in-house strain of 
ApcMin/+ mice, which were bred and kept in a 
conventional animal facility, monitored three times a 
week and given access to standard diet and water ad 
libitum. Two weeks prior to the imaging experiment 
the animals were kept on a chlorophyll free diet.  
To perform the imaging experiments, we made 
use of a CD44v6-targeting peptide, which previously 
demonstrated its applicability in a 
CD44v6-overexpressing preclinical cancer model (11); 
To accomplish fluorescence imaging, we labeled the 
14-amino-acid peptides, directed against mouse 
CD44v6 (specific peptide; QETWFQNGWQGKN) and 
human CD44v6 (control peptide; 
KEQWFGNRWHEGYR), with a commercially 
available fluorophore DY-681 (Dyomics GmbH, Jena, 
Germany). CD44v6 peptides are species-specific and 
do not cross-react (11-13). By labeling the peptides 
with the fluorescent dye, we created tracer products 
(CD44v6*DY-681) that are fluorescent in the far red 
light spectrum (absorption max: 691nm / emission 
max: 708 nm).  
During the experiment, 12-16 week-old ApcMin/+ 
mice received an intravenous (IV) tracer injection 
[CD44v6*DY-681, mouse-specific or control peptide 
(human-targeting); 1mg/kg] and were sacrificed 2 
hours later. Ex vivo fluorescence imaging of the 
longitudinally opened small intestines was 
performed, using the fresh or formalin-fixed 
specimens. In total, six mice received the specific, 
mouse-targeting, tracer product. As control, six mice 
received the human-targeting tracer product and 
three mice were imaged at baseline (without tracer 
administration). Ex vivo white-light and fluorescence 
imaging was performed for the harvested organs for 
both 700 and 800 nm emission wavelengths, using a 
Pearl Impulse Small Animal Imaging System (LI-COR 
Biosciences, Bad Homburg, Germany). All images 
were acquired at a fixed distance, using the same 
channel settings (exposure times, laser intensities). 
Post-imaging processing of the files and visual 
fluorescence scaling, in order to accomplish adequate 
visual comparison, was performed using ImageJ 
software Vers. 1.48 (ImageJ, U.S. National Institutes of 
Health, Bethesda, MD, USA). 
Statistical analyses  
We performed a two-class comparison between 
FGmRNA profiles of adenomas and healthy control 
colorectal mucosa. The two-sample Student t-test was 
used to detect significant differences in FGmRNA 
expression. To control the false discovery rate, we 
performed a multivariate permutation (MVP) test 
with a false discovery rate (FDR) of 5% and a 
confidence interval (CI) of 80%. The identified 
FGmRNA overexpressing genes were ranked and 
listed according to the level of significance. For IHC 
analysis, the difference in staining intensities and 
distribution among the three LS disease stages (LGD, 
HGD and carcinoma) was analyzed using the 
non-parametric Kruskal-Wallis test (IBM SPSS 22.0.0; 
IBM Corporation, Armonk, NY, USA). For the 
statistical analyses of the IHC results P values < 0.05 
were considered significant. 
Results 
Functional genomic mRNA profiling identifies 
differentially expressed genes in sporadic 
colorectal adenomas 
FGmRNA-profiling was applied to publicly 
available expression profiles of 26 normal colon 
mucosa samples and 47 adenoma samples. After 
multivariate permutation testing, we identified 4 524 
genes that show FGmRNA overexpression in 
adenoma samples compared to normal colon tissue 
(FDR 5%, CI 80% - Table S1).  
Ex vivo validation of protein expression: 
AXIN2, CEMIP, CD44 and JUN 
To determine whether the 
FGmRNA-overexpressing genes could be translated 
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into differences at the protein level, we analyzed the 
downstream protein expression for the top five genes 
in sporadic adenomas via immunohistochemistry 
(IHC). Since the FGmRNA-profiling results are 
ranked according to their level of significance, at least 
the top FGmRNA-overexpressing genes should show 
an observable difference at the protein level. In 
addition, validation of the top five 
FGmRNA-overexpressing genes provided a complete 
cellular coverage, as we were able to evaluate protein 
expression at each cellular location (e.g. cytoplasm, ER 
membrane, cell surface and nucleus).  
Figure 1A contains the IHC results and the 
representative images of the IHC stainings, showing a 
cytoplasmic and/or membranous staining pattern 
with an overall high staining intensity for the proteins 
Axin-2, CEMIP and CD44. For these three proteins, 
the majority of samples showed a positive staining of 
the dysplastic epithelial cells (78-96%; incl. 
intermediate and high staining intensities). For CD44, 
85% of the sporadic adenoma tissue samples were 
positive (22/26), of which the vast majority (86%; 
19/22) expressed a high staining intensity. It should 
be noted that CD44 is present on both the epithelial 
cells and in the stromal extracellular regions, 
including lymphocytes and macrophages (14). We 
observed that the panCD44-antibody, recognizing 
CD44s as well as CD44v antigens, also strongly 
stained the surrounding stromal tissue (Figure S1). 
The anti c-Jun staining shows a nuclear staining 
pattern, with an overall intermediate intensity score. 
Unfortunately, we were not able to optimize the 
staining of CELF2, so protein expression for this target 
could not be evaluated. Figure 1B demonstrates that 
for all four evaluated targets, Axin-2, CEMIP, CD44 
and c-Jun, a significant difference in staining intensity 
between adenoma tissue and the adjacent normal 
mucosa could be observed (P < 0.001).  
Target selection in sporadic adenomas: 18 
possible imaging targets identified  
The localization of the protein products 
determines whether they could be suitable as an 
imaging target. Cell membrane receptors and specific 
extracellularly secreted proteins are presumed to be 
the most attractive targets. This is because proteins on 
the cell surface or extracellular space are more easily 
accessible for targeting monoclonal antibodies or 
peptide probes, following both systemic and local 
administration. Furthermore, imaging targets should 
preferably be restricted to the adenomatous tissue, for 
example by anchoring or binding to membrane 
receptors. This enables ‘highlighting’ of the aberrant 
area and fluorescent visualization during endoscopy. 
Therefore, we categorized the protein products of the 
top fifty FGmRNA-overexpressing genes based on 
their subcellular localizations (Figure 2 - based on 
http/www.proteinatlas.org, http://www.genecards.
org). 
Figure 2 depicts the first 50 genes encoding 
proteins and their subcellular localization. By 
categorizing the proteins based on their localization, 
thus identifying cell membrane receptors and specific 
extracellularly secreted proteins, 18 proteins were 
selected that could serve as potential imaging targets, 
including CD44.  
CD44 as a potential target in sporadic and 
high-risk CRC populations  
Based on the degree of FGmRNA 
overexpression, the downstream protein upregulation 
and cellular membrane localization, we identified 
CD44 as an attractive target in sporadic adenomas. To 
determine whether CD44 would be of similar interest 
in high-risk CRC populations, we performed IHC on 
adenomatous and carcinomatous Lynch lesions. 
Figure 3A-C depicts representative images of both 
dysplastic and carcinomatous polyps, demonstrating 
the presence of CD44 throughout the complete 
adenoma-carcinoma sequence. The majority of the 
LGD, HGD and carcinoma samples showed positive 
epithelial staining results (Figure 3D, 46-73%; incl. 
intermediate and high staining intensities), with a 
reversed intensity-trend within the 
adenoma-carcinoma sequence (P = 0.006). All the 
adjacent normal mucosa, independent of the 
adenoma-carcinoma disease stage, showed weak to 
negative CD44 expression. 
CD44v6-targeted fluorescence imaging of 
intestinal adenomas  
It was previously established that the CD44 
glycoproteins are potentially important components 
in CRC development (15), demonstrating 
tumor-initiating properties (16). In contrast to the 
standard CD44 isoform, expression in normal tissues 
is highly restricted for its v6 splice variant (17). 
CD44v6 has shown to be a prognostic factor in various 
solid cancer types, including colorectal carcinoma 
(18,19), and recent research demonstrated that 
CD44v6 expression is superior to CD44 expression, at 
least in respect to assessing the prognosis and clinical 
usefulness in sporadic CRC. Since CD44v6 is known 
to be functionally involved in intestinal tumorigenesis 
(20), and overexpression of this splice variant has 
been described to occur already early in the 
adenoma-carcinoma sequence (21), we wanted to 
investigated its imaging potential in precancerous 
intestinal lesions. 
First of all, to confirm the hypothesized CD44v6 
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overexpression in sporadic adenomatous polyps, we 
performed an extended IHC analysis (n=69; Figure 
4A-C). Figure 4D depicts that 86% of the samples 
showed indeed a positive epithelial staining (incl. 
intermediate and high staining intensities), of which 
the majority was of high intensity. Both the adjacent 
normal mucosa, as well as the surrounding stromal 
tissue, showed weak to negative results (n=52). 
Secondly, the membranous overexpression of CD44v6 
observed in the adenomatous APCMin/+ mice crypts 
confirms the suitability of this specific animal model 
for CD44v6-targeted imaging experiments (Figure 
5A).  
 
Figure 1. Immunohistochemistry results of sporadic adenomas. (A) Table presenting IHC results of the four targets; the mean intensities and distribution within the 
different staining categories are presented using the H-score (Cohen’s Kappa coefficient for inter-observer agreement: 0.485) (B) Representative images of strong staining 
intensities per target (brown), where the first two show a cytoplasmic staining, CD44 a membrane staining and c-Jun a staining of the nucleus. (C) Immunohistochemistry results 
of sporadic adenomas and their surrounding normal tissue, illustrating the significant difference in staining intensities between dysplasia and normal colon crypts per marker. Bar 
graphs demonstrating the differences observed in staining intensities (H-scores) between dysplasia and adjacent normal colon mucosal crypts per marker. ** P value < 0.001 
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Figure 2. Cellular localization of protein products of the first 50 FGmRNA-overexpressing genes. The cell membrane and extracellular proteins that are restricted 
to the tumor site (e.g. by anchoring or binding to membrane receptors) are especially suitable as imaging targets (black circles). This results in already 18 potential imaging targets, 
including CD44. The top-five genes are represented in bold; genes with products at multiple locations are italicized. ER, endoplasmic reticulum. 
 
Figure 3. CD44 immunohistochemistry (IHC) results in high-risk Lynch lesions. Representative images of strong CD44 epithelial staining intensities (brown) in 
respectively LGD (A), HGD (B) and carcinoma samples (C). The high staining intensity in the aberrant crypts is in contrast to the CD44-negative surrounding normal colon 
tissue. (D) Bar graph presenting IHC results (H-score) for CD44 in Lynch lesions, illustrating a significant difference in staining intensity within the adenoma- carcinoma sequence. 
* P value < 0.05 
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Figure 4. Immunohistochemistry (IHC) results for CD44v6 in sporadic adenomas. (A) Representative image of a strong staining intensity in high-grade adenomatous 
tissue, (B) and negative staining results in complete healthy colon crypts. (C) Representative image of the difference in CD44v6 staining intensity between normal and dysplastic 
colon crypts (dashed yellow lines). (D) H-score results for the extended sample-size (n = 69), resulting in an overall high CD44v6 staining intensity.  
 
Figure 5. Results of CD44v6-targeted fluorescent imaging in ApcMin/+ mice. (A) CD44v6 overexpression can be observed in the cell membranes of the adenomatous 
crypts of the APCMin/+ mice, which confirms the suitability of this specific animal model for CD44v6-targeted imaging experiments. (B) Representative images of fresh resected and 
formalin-fixed murine intestines, previously injected with the specific (mouse-targeting) CD44v6*DY-681 fluorescent peptide tracer. The images illustrate the positive imaging 
results, as the fluorescent peaks correspond to the polyps identified on the white-light images (arrow heads) and moreover demonstrate the consistency of the observed signals 
among the different animals (n = 4). (C) Representative images of fresh and formalin-fixed murine intestines, previously injected with either the control CD44v6*DY681 tracer 
(human-targeting, n = 4) or no tracer (n = 2), demonstrating low to negative background signals in both control conditions. 
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Our results show that a clear difference in 
fluorescent signals could be observed between the 
specific CD44v6-targeting tracer and the control 
conditions (human-targeting peptide and no peptide 
tracer). When using the specific (mouse-targeting) 
tracer product, high fluorescent signals can be 
visualized in the – dye specific – 700 nm channel 
(Figure 5B). Positive fluorescent results could be 
observed for the adenoma-containing intestines, 
urine-containing bladder and in a limited amount for 
the kidneys; the other harvested organs did not 
display any fluorescence (Figure S2 A). In contrast, 
low to negative fluorescent signals can be observed at 
baseline (no peptide) and following aspecific 
(human-targeting) tracer administration (Figure 5C 
and Figure S2 B). At 800 nm wavelengths, low 
fluorescent signals are present, fitting the emission 
spectrum of the fluorophore (Figure S3). The negative 
control results and the absence of non-specific 
emission signals together indicate the authenticity of 
the specific (mouse-targeting) CD44v6*DY-681 
fluorescent results. Therefore, these imaging results 
confirm what we expected based on our 
FGmRNA-profiling results: CD44v6 is indeed an 
attractive target for intestinal adenoma imaging. In 
addition, our results show that wide-field, ‘red-flag’ 
molecular imaging of intestinal adenomas is feasible 
when using an intravenously administered, 
fluorescently labeled small peptide drug. 
Discussion 
CRC is a highly lethal condition and early 
endoscopic identification and removal of its precursor 
lesions, adenomatous polyps, could prevent this 
disease from developing. Molecular guided 
endoscopy has the potential to improve adenoma 
detection. This study presents an extensive list of 
FGmRNA-overexpressing genes that may serve as 
potential targets for molecular colorectal adenoma 
imaging. Based on protein location of the first 50 
FGmRNA-overexpressing genes, i.e. membrane 
bound or extracellular, we were able to identify 18 
potential targets for molecular imaging. We validated 
our FGmRNA results by demonstrating the 
differences in downstream protein expression levels 
between adenoma and normal colon tissue for the top 
FGmRNA-overexpressing genes. Based on the degree 
of FGmRNA-overexpression, the downstream protein 
membrane localization and cellular protein 
expression level, we identified CD44 as an attractive 
adenoma target in both sporadic adenomas and 
high-risk Lynch patients. In addition, we 
demonstrated the feasibility of CD44v6-targeted 
adenoma imaging, as we were able to fluorescently 
visualize adenomas in ApcMin/+ mice.  
We are the first to perform molecular 
characterization of adenomas based on FGmRNA 
expression profiles. Genomic alterations can have 
downstream effects by changing gene and protein 
expression levels. Therefore, exploration of genomic 
alterations and the molecular downstream effects, 
specifically occurring in adenomas, might result in the 
identification of new imaging targets. However, 
although genomic alterations affect the expression 
levels of genes, they are in general overshadowed by 
non-genetic factors. Our FGmRNA-profiling method 
is capable of correcting this gene expression data for 
influencing non-genetic factors, allowing an enhanced 
view on gene expression levels (7). This enhanced 
view allows us to reanalyze and reinterpret publicly 
available adenoma expression profiles. The fact that 
the genes that show the most FGmRNA upregulation 
differ from the previously published results derived 
with use of the same expression profiles (8), at the 
time assessed without the FGmRNA-profiling 
method, strengthen the believe that we are able to 
provide new insights in pre-existing data. 
Interestingly, our top identified and validated genes, 
AXIN2, CEMIP, CD44 and JUN, are all known 
target-genes of the Wnt-signaling pathway (Figure 
S4). The Wnt-pathway is a well-known initiator of the 
adenoma-carcinoma sequence, illustrating the 
biological relevance of the identified genes (2,22). 
Thus, in addition to selecting potential targets for 
molecular imaging strategies, the genes we identified 
via FGmRNA-profiling also reflect the biology of the 
adenoma-carcinoma sequence. In this report we 
present an extensive, publicly accessible list of 
additional FGmRNA-overexpressing genes, which 
may contain other promising targets and could serve 
as a source to select new targets for molecular 
adenoma imaging (Table S1). However, it should be 
noted that, although FGmRNA-profiling can serve as 
a tool for identifying cancer associated genetic 
alterations with consecutive protein upregulation, it is 
unable to distinguish different gene splice variants. 
Since molecular imaging could facilitate early 
lesion detection, this advanced imaging technique 
could be of high value; especially when considering 
high-risk CRC populations, such as patients with 
Lynch syndrome (LS). The role of CD44 in the 
adenoma-carcinoma sequence has been previously 
established (15,16,20,23-30). No results have yet been 
published on the role of CD44 in LS. In this study we 
demonstrate that CD44 is indeed overexpressed in LS 
adenomas and carcinomas. Its previously established 
biological role, combined with its demonstrated 
epithelial overexpression in sporadic and high-risk 
Lynch adenomas, makes CD44 an interesting imaging 
target; especially when targeting one of its epithelial 
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splice variants and therefore limiting surrounding 
stromal involvement. Our results evidence the 
suggested adenoma-imaging potential of CD44v6: 
first of all, we have shown that the majority of 
sporadic adenomas indeed overexpress this particular 
epithelial splice protein, which is in concordance with 
literature (21,31,32). Even more importantly, our ex 
vivo imaging results clearly demonstrate that, with 
use of a fluorescently labeled CD44v6-targeting 
peptide, wide-field ‘red flag’ adenoma detection can 
be accomplished. We are the first to describe 
preclinical wide-field fluorescent imaging of CD44v6 
using an IV injected fluorescent CD44v6 targeted 
peptide. Compared to other cancer types (11,33), no 
data has yet been published regarding 
CD44v6-targeting peptides in the context of colorectal 
cancer or adenomas. In addition, our approach makes 
for a ‘red-flag’ adenoma identification strategy, 
suitable for future clinical translation. Firstly, it is 
based on a peptide tracer product, which is an 
attractive molecular targeting probe due to its relative 
small-sized structure, reduced immunogenicity and 
low large-scale production costs (34). And secondly, 
recent technical advances have let to the availability of 
endoscopic wide-field molecular imaging systems, 
suitable for clinical use (35-37). 
 Recently, the first in-human molecular targeted 
endoscopy results on the detection of colorectal 
polyps were published, using an intravenously 
administered peptide probe against c-Met (37); They 
reported that the adenoma identification increased 
with 19% when using c-Met targeted fluorescence 
endoscopy compared to white-light inspection. These 
results support our findings, since we identified MET 
to be among the 50 highly significant 
FGmRNA-overexpressing genes and denoted the 
c-Met protein as one of the 18 potential imaging 
targets (see Figure 2). In addition, the clinical potential 
of our molecular-targeted imaging approach is 
indicated by a recent clinical trial with a 89Zr-labeled 
CD44-targeting antibody, which showed the 
feasibility of tumor-targeted imaging by positron 
emission tomography (PET)(38), and a preceding case 
report that described microscopic crypt 
characterization on resected human colonic tissue 
with use of confocal laser endomicroscopy (CLE) after 
ex vivo topical application of fluorescein- 
isothiocyanate labeled CD44v6 antibodies (39).  
Conclusion 
We have shown that our bioinformatics and 
functional approach can identify biologically relevant 
targets that are potentially applicable for molecular 
imaging strategies. We have not only identified CD44 
as an attractive colorectal adenoma target, but have 
also demonstrated the applicability of a small peptide, 
targeting its splice variant CD44v6, for molecular 
imaging purposes. Moreover, the availability of a 
human CD44v6-targeting peptide enables clinical 
translation of these results in de near future. Since the 
same need for diagnostic improvements exists for 
other – gastrointestinal – cancers, we envision a 
similar molecular target identification approach for a 
wide range of tumors, including esophageal, stomach 
and pancreatic cancer.  
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